Memorial Sloan Kettering Cancer Center

This early-phase trial tested whether combining two drugs, vemurafenib and copanlisib, could make thyroid cancers that no longer respond to radioiodine treatment sensitive to it again. The study included 8 adults with advanced BRAF-mutant thyroid cancer. The main goal was to find…

This study tested whether using local ablative therapy (LAT) — treatments like radiation or heat to destroy tumors — can control metastatic non-small cell lung cancer when a blood test shows rising cancer DNA (MRD). 37 participants received LAT instead of switching to stronger dr…

This study tested a combination of two drugs, talazoparib and temozolomide, in 16 men with advanced prostate cancer that had spread and stopped responding to hormone therapy. The goal was to find the safest dose and see if the treatment could shrink tumors. While the approach aim…

This study tested whether a new pump and catheter system can safely deliver chemotherapy directly to the liver in 35 people with colorectal cancer or bile duct cancer that has spread. The goal was to see if this approach causes fewer side effects than standard treatment. Particip…

This study tested a precise type of radiation called proton therapy for head and neck cancer that returned after previous radiation. 87 adults whose tumors could not be surgically removed received this treatment. The goal was to see how well it controls the cancer and what side e…

This study tested two immunotherapy drugs, nivolumab and ipilimumab, in 64 people with salivary gland cancer that had come back or spread. The goal was to see how well the drugs shrank tumors and what side effects occurred. The approach aims to control the disease, not cure it, a…

This early-phase study tested the safety of combining two targeted drugs, dacomitinib and osimertinib, in 22 people with a specific type of advanced lung cancer (EGFR-mutant) that had not been treated with similar drugs before. The goal was to find the highest safe dose and see h…

This study tested the drug regorafenib in 38 people with a rare cancer called adenoid cystic carcinoma that had spread or come back. Regorafenib is already approved for other cancers, but this trial used a lower starting dose to reduce side effects. The goal was to see if the dru…

This study looked at whether screening cancer caregivers for distress and then offering them targeted support (the S+C approach) is better than usual care. 150 caregivers of cancer patients took part. The goal was to see if this approach reduces caregivers' unmet needs and improv…

This study gathered information from 12 people with fibrolamellar cancer (FLC) around the world. Researchers collected medical history and details of regular care to build a registry for future studies. No treatment was given. The goal is to better understand this rare liver canc…